Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07780656 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 4 more changesShow less
    • Trial sites expanded: 0 → 4 locations
    • Start date changed from estimate of Aug 31, 2026 to Sep 11, 2026
    • Eligibility criteria expanded, about 17 words
    • Secondary endpoints: details revised at 2 of 5 entries
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
GlaxoSmithKline
246 trials monitored
See 20 trials at risk
COPD
1,119 trials monitored
See 34 trials at risk
The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.
Trial Details
NCT Number NCT07780656
Lead Sponsor GlaxoSmithKline
Conditions
(from sponsor)		 Pulmonary Disease, Chronic Obstructive
Related terms Pulmonary Disease, Chronic Obstructive
Enrollment 624 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov